Myopathy is an adverse effect of telbivudine. We describe a case of telbivudine-induced myopathy visualized on FDG PET/CT in a 75-year-old man with history of chronic HBV infection and hepatocellular carcinoma. FDG PET/CT images demonstrate no abnormal uptake characteristic of hypermetabolic malignancy. However, intense hypermetabolic activity in muscles of the abdominal wall was noted. Three months after telbivudine withdrawal, a second FDG PET/CT showed normal muscle activity in the abdominal wall.
基金：
National Natural Science Foundation of China [81671718, 81873903]; Natural Science Foundation of Hubei province in China [2016CFB687, 2011CDB551]; Clinical Foundation of Tongji Hospital [2015C013]
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Nucl Med, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Hosp, PET CT, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Zou Sijuan,Cheng Zhaoting,Song Shuang,et al.Telbivudine-Induced Myopathy Incidentally Detected by FDG PET/CT Imaging in a Patient With History of Hepatocellular Carcinoma[J].CLINICAL NUCLEAR MEDICINE.2019,44(2):171-172.doi:10.1097/RLU.0000000000002385.
APA：
Zou, Sijuan,Cheng, Zhaoting,Song, Shuang,Zhu, Dongling&Zhu, Xiaohua.(2019).Telbivudine-Induced Myopathy Incidentally Detected by FDG PET/CT Imaging in a Patient With History of Hepatocellular Carcinoma.CLINICAL NUCLEAR MEDICINE,44,(2)
MLA：
Zou, Sijuan,et al."Telbivudine-Induced Myopathy Incidentally Detected by FDG PET/CT Imaging in a Patient With History of Hepatocellular Carcinoma".CLINICAL NUCLEAR MEDICINE 44..2(2019):171-172
